UPPSALA, Sweden, Feb. 8, 2024 /PRNewswire/ — Positive EBITDA in H2 setting the target for FY 2024
Q4 2023 highlights
Total net revenues of SEK 166.0 m (156.1)
EBITDA of SEK 12.4 m (-53.1), EBITDA excluding costs for legal processes and external non-repeating clinical trials, SEK 23.4 m (-0.1)
Net earnings of SEK -18.6 m (-91.8)
US Pharma segment (Zubsolv® US) net revenues of SEK 151.3 m (142.6), in local currency USD 14.2 m (13.3), US Pharma EBIT of SEK 75.4 m (77.0)
Cash flow from operating activities of SEK -2.6 m (-48.9), cash and invested funds of SEK 171.0 m (351.9)
Earnings per share before and after dilution amounted to SEK -0.54 (-2.67)
The MODIA® study didn’t meet the primary end-points, but showed high rates of treatment response in both study arms, with no adverse events associated with the use of MODIA
Robin Evers elected as board member at the Extraordinary General Meeting. He replaces Henrik Kjaer Hansen who has resigned. Kjaer Hansen has instead been appointed chairman of the Nomination Committee, representing Novo Holdings A/S.
FDA accepted the New Drug Application filing for review of OX124, a high-dose rescue medication for opioid overdose with naloxone
Financial outlook provided for 2024 on page 15.
Important events after the end of the period
MODIA and Vorvida® will be reimbursed within the US Veterans Affairs Federal Supply Schedule as of January 1, 2024.
SEK m unless otherwise stated
2023
Oct-Dec
2022
Oct-Dec
2023
Jan-Dec
2022
Jan-Dec
Net revenues
166.0
156.1
638.8
Leave a Reply